Zara Baloch, Review Editor | Editorial Board Member at OncoDaily, Director Quantitative Research and Meta Analysis, Digital Education Manager and Host at MedNews Week, shared on LinkedIn:
“What if the next major breakthrough in stem cell transplantation isn’t a new treatment, but a better way of delivering care?
In our latest MedNews Week Keynote Conference, featured on OncoDaily TV, we had the privilege of welcoming Dr. Shernan Holtan for an insightful discussion on the evolving landscape of transplantation and cellular therapy.
From advances in graft-versus-host disease (GVHD) prevention and post-transplant cyclophosphamide (PTCy) to donor selection and individualized treatment strategies, the conversation went beyond clinical innovation to explore an equally important challenge: making these therapies more accessible to patients.
One of the most thought-provoking aspects was whether more intensive treatment always translates into better outcomes, and how standardized care pathways can coexist with individualized patient needs.
Dr. Holtan also emphasized the importance of rethinking care delivery, reducing unnecessary complexity, and addressing the practical barriers that prevent patients from accessing potentially life-saving treatments.
Progress in medicine isn’t measured only by the treatments we develop, but also by how effectively we deliver them to the people who need them.
A sincere thank you to Dr. Shernan Holtan for sharing her expertise, and to Dr. Yan Leyfman, Dr. Chandler Park, and the entire MedNews Week team for making these conversations possible.
Watch the full keynote on OncoDaily TV: How Transplant System Redesign Is Transforming GVHD, Outcomes and CAR-T Access.
Ayesha Junaid, a final-year MBBS student at Dow Medical College, added:
“What good is a potentially life-saving therapy if most eligible patients never receive it?
One of the most striking points from Dr. Shernan Holtan’s discussion was the substantial gap in access to transplantation and cellular therapy, with only about 1 in 5 eligible patients actually receiving these treatments.
It raises an important question: Are we making the same progress in delivering these therapies as we are in developing them?
A powerful reminder that advancing medicine isn’t just about scientific breakthroughs, but also about ensuring those breakthroughs reach the patients who need them.
Grateful to Dr. Holtan for highlighting this important challenge, and to the MedNews Week team for bringing these conversations forward!”
You can also read: CAR-T vs Stem Cell Transplantation: Where Are Practice and Science Heading in 2026?
